Table 2 Incidence of adverse cardiac events with immunotherapy
From: Cardiotoxicity risk factors with immune checkpoint inhibitors
|  | Atrial Fibrillation with RVR | HFpEF | HFrEF | Myocarditis | Pericarditis | VF/VT | Total Cardiac Events (N = 34) N (% rate per agent) |
|---|---|---|---|---|---|---|---|
Immune Checkpoint Inhibitor Agent | |||||||
 Durvalumab (n = 36) N (%)1 | 1 (2.8%)1 | 0 | 1 (2.8%)1 | 0 | 0 | 0 | 2 (5.6%) |
 Ipilimumab (n = 39) N (%)1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 Nivolumab (n = 220) N (%)1 | 4 (1.8%)1 | 0 | 1 (0.5%)1 | 0 | 5 (2.3%)1 | 1 (0.5%)1 | 11 (5%) |
 Pembrolizumab (n = 243) N (%)1 | 6 (2.5%)1 | 2 (0.8%)1 | 4 (1.6%)1 | 0 | 7 (2.9%)1 | 2 (0.8%)1 | 21 (8.6%) |
Type of Malignancya | Â | Â | Â | Â | Â | Â | Â N (% rate per malignancy subtype) |
 Endometrial (n = 2) N (%)1 | 0 | 0 | 1 (50%)1 | 0 | 0 | 0 | 1 (50%) |
 Esophageal (n = 4) N (%)1 | 1 (25%)1 | 0 | 0 | 0 | 0 | 0 | 1 (25%) |
 Non-Small Cell Lung (n = 254) N (%)1 | 10 (3.9%)1 | 2 (0.8%)1 | 3 (1.2%)1 | 0 | 12 (4.7%)1 | 2 (0.8%)1 | 29 (11.4%) |
 Small Cell Lung (n = 30) N (%)1 | 0 | 0 | 1 (3.3%)1 | 0 | 0 | 0 | 1 (3.3%) |
 Squamous Cell Carcinoma (n = 2) N (%)1 | 0 | 0 | 1 (50%)1 | 0 | 0 | 1 (50%)1 | 2 (100%) |
 Total (n = 538) N (%)2 | 11 (2.0%)2 | 2 (0.4%)2 | 6 (1.1%)2 | 0 (0%)2 | 12 (2.2%)2 | 3 (0.6%)2 |  |